All relevant data are within the paper and its Supporting Information files. Summary association statistics from meta-analyses are available from dbGAP at accession number phs000930.

Introduction {#sec001}
============

Obesity is a worldwide public health epidemic, with current US estimates of 37.9% obese and 7.7% morbidly obese adults \[[@pgen.1006719.ref001]\]. Disparities in obesity rates, as well as rates of comorbidities and mortality, are evident across sex and racial/ethnic groups. Estimates from NHANES for 2013--2014 \[[@pgen.1006719.ref001]\] show that obesity is more prevalent among African Americans (48.5%) than among non-Hispanic Whites (37.1%). In addition, obesity rates are higher among African American women (57.2%) than among African American men (38.2%). For comparison, the obesity rates in non-Hispanic Whites were 38.7% and 35.4%, respectively, for women and men.

Genome-wide association studies (GWAS) in diverse populations have identified \> 300 loci associated with measures of adiposity including body mass index (BMI) and waist-to-hip ratio (adjusted for BMI, WHR~adjBMI~) in populations of European \[[@pgen.1006719.ref002]--[@pgen.1006719.ref009]\], African \[[@pgen.1006719.ref010]--[@pgen.1006719.ref012]\], and East Asian ancestry \[[@pgen.1006719.ref013]--[@pgen.1006719.ref015]\]. The majority of associated variants are common (MAF \>5%) with small effect size, and jointly explain only a fraction of the phenotypic variances \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\]. It has long been hypothesized that low frequency (MAF = 0.5--5%) and rare (MAF \< 0.5%) variants may also contribute to variability in complex traits. However, these variants are not well captured in previous GWAS imputed to the HapMap reference panel \[[@pgen.1006719.ref016]--[@pgen.1006719.ref017]\]. The availability of higher density reference panels such as the 1000 Genomes Project (38M variants in 1092 individuals from phase 1) \[[@pgen.1006719.ref018]\] has demonstrated improved imputation quality in European populations particularly for low frequency variants (aggregate R^2^ \~0.6 for MAF = 0.5%). However its impact is less clear for non-European populations \[[@pgen.1006719.ref019]\]. We took this opportunity to use higher density imputation to reevaluate our previous GWAS for associations with anthropometric traits in individuals of African ancestry (AA) including African Americans and Africans.

The African Ancestry Anthropometry Genetics Consortium (AAAGC) previously identified seven genome-wide significant loci for BMI in up to 71,412 AA individuals, and an additional locus when combined with European ancestry (EA) data from the Genetic Investigation of ANthropometric Traits (GIANT) consortium using GWAS imputed to the HapMap Phase 2 reference panel \[[@pgen.1006719.ref011]\]. No genome-wide significant loci were identified for WHR~adjBMI~ in a GWAS of up to 27,350 AA individuals \[[@pgen.1006719.ref012]\]. The low yield of discovery in AA studies is likely due to their relatively smaller sample sizes in comparison to EA studies \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\], as well as their lower degree of linkage disequilibrium (LD) and thus poorer imputation quality. Here, we extended our previous work in the AAAGC to perform meta-analyses and replication of GWAS imputed to the 1000 Genomes reference panel in up to 52,895 AA individuals for BMI and up to 23,095 AA individuals for WHR~adjBMI~. We aimed to 1) discover novel variants, 2) fine map established loci, and 3) evaluate the coverage and contribution of low frequency variants in genetic associations in AA populations.

Results {#sec002}
=======

Study overview {#sec003}
--------------

We conducted sex-combined and sex-stratified meta-analyses of GWAS summary statistics across 17 studies for BMI (N = 42,752) and 10 studies for WHR~adjBMI~ (N = 20,384) in AA individuals in stage 1 discovery ([S1](#pgen.1006719.s012){ref-type="supplementary-material"} and [S2](#pgen.1006719.s013){ref-type="supplementary-material"} Tables, [S1 Fig](#pgen.1006719.s001){ref-type="supplementary-material"}). Missing genotypes in individual studies were imputed to the 1000 Genomes Project cosmopolitan reference panel (Phase I Integrated Release Version 3, March 2012) \[[@pgen.1006719.ref018]\] using MaCH/minimac \[[@pgen.1006719.ref020]\] or SHAPEIT2/IMPUTEv2 \[[@pgen.1006719.ref021]--[@pgen.1006719.ref022]\] ([S3 Table](#pgen.1006719.s014){ref-type="supplementary-material"}). Among all variants with MAF ≥ 0.1% in the largest Women's Health Initiative (WHI) study, the average info score was 0.81 and 90.5% had imputation info score ≥ 0.3 ([S4 Table](#pgen.1006719.s015){ref-type="supplementary-material"}). Genomic control corrections were applied to each study and after meta-analysis (λ = 1.07 for BMI, 1.01 for WHR~adjBMI~) ([S3 Table](#pgen.1006719.s014){ref-type="supplementary-material"}, [S2](#pgen.1006719.s002){ref-type="supplementary-material"}--[S5](#pgen.1006719.s005){ref-type="supplementary-material"} Figs). Association results for \~18M variants for BMI and \~21M variants for WHR~adjBMI~ were subsequently interrogated further.

From stage 1 meta-analyses, variants associated with BMI (3,241 in all, 1,498 in men, 2,922 in women) and WHR~adjBMI~ (2,496 in all, 1,408 in men, 2,827 in women) at *P* \< 1×10^−4^ were carried forward for replication in AA and EA. Stage 2 included 10,143 AA (2,458 men and 7,685 women) for BMI and 2,711 AA (981 men and 1,730 women) for WHR~adjBMI~ analyses. Stage 3 included 322,154 EA (152,893 men and 171,977 women) for BMI and 210,086 EA (104,079 men and 116,742 women) for WHR~adjBMI~ analyses by imputing HapMap summary statistics results \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\] to 1000 Genomes \[[@pgen.1006719.ref023]\] ([S1 Fig](#pgen.1006719.s001){ref-type="supplementary-material"}). Meta-analyses were performed to combine either sex-combined or sex-specific results from AA (stages 1+2, N ≤ 57,895 for BMI, ≤ 23,095 for WHR~adjBMI~ in sex-combined analyses) and both AA and EA (stages 1+2+3, N ≤ 380,049 for BMI, ≤ 233,181 for WHR~adjBMI~ in sex-combined analyses, [S6](#pgen.1006719.s006){ref-type="supplementary-material"}--[S9](#pgen.1006719.s009){ref-type="supplementary-material"} Figs). Variants that reached genome-wide statistical significance (*P* \< 5×10^−8^) were assessed for generalization of associations with BMI to children in two additional AA cohorts (N = 7,222).

Genome-wide significant loci in meta-analyses {#sec004}
---------------------------------------------

### Sex-combined analyses {#sec005}

In the sex-combined meta-analysis of BMI in AA, seven previously established European or African ancestry-derived loci in/near *SEC16B*, *TMEM18*, *GNPDA2*, *GALNT10*, *KLHL32*, *FTO* and *MC4R* reached genome-wide significance (*P* \< 5×10^−8^) ([Table 1](#pgen.1006719.t001){ref-type="table"}, [S6](#pgen.1006719.s006){ref-type="supplementary-material"} and [S10A](#pgen.1006719.s010){ref-type="supplementary-material"} Figs). The rs7708584 variant at *GALNT10* had the lowest *P*-value (*P* = 4.2×10^−14^) and was the same lead variant as reported in our previous AA study ([S5 Table](#pgen.1006719.s016){ref-type="supplementary-material"}) \[[@pgen.1006719.ref011]\]. The association at *KLHL32* was specific to the AA population as the lead variant was not statistically significant in EA (*P* \> 0.05), consistent with our previous finding ([S5 Table](#pgen.1006719.s016){ref-type="supplementary-material"}) \[[@pgen.1006719.ref011]\]. No additional novel BMI loci were identified after meta-analysis of AA and EA data. Two previously reported loci in AA, *ADCY3* and *MIR148A-NFE2L3* \[[@pgen.1006719.ref011]\], did not reach genome-wide significance in the present study. The previously reported lead variant at *ADCY3*, rs7586879, showed weaker effect and association in AA (effect = 0.047, *P* = 3.60×10^−8^ \[[@pgen.1006719.ref011]\] vs. effect = 0.032, *P* = 1.05×10^−4^, this study). On the other hand, a moderately correlated (r^2^ = 0.52 in AFR) variant, rs10203482, show stronger association at *P* = 3.35×10^−7^ ([S5 Table](#pgen.1006719.s016){ref-type="supplementary-material"}). At *MIR148A/NFE2L3*, the previously reported lead variant identified by meta-analysis of AA and EA, rs10261878, also showed weaker association in the current study primarily due to weak association in EA (*P* = 4.10×10^−5^ in AA, 4.69×10^−3^ in EA and 2.10×10^−5^ in AA+EA) ([S5 Table](#pgen.1006719.s016){ref-type="supplementary-material"}). For WHR~adjBMI~, an established locus (*ADAMTS9-AS2*) ([S10B Fig](#pgen.1006719.s010){ref-type="supplementary-material"}) and a novel locus (*TCF7L2/HABP2*) ([Fig 1A](#pgen.1006719.g001){ref-type="fig"}) showed significant associations, the latter lead variant rs116718588 was low frequency (MAF = 0.045, [Table 1](#pgen.1006719.t001){ref-type="table"}). Meta-analyses including both AA and EA individuals revealed an additional novel locus at *SPRYD7/DLEU2* for WHR~adjBMI~ ([Table 1](#pgen.1006719.t001){ref-type="table"}, [Fig 1A](#pgen.1006719.g001){ref-type="fig"} and [S7 Fig](#pgen.1006719.s007){ref-type="supplementary-material"}). Overall, all the BMI associated lead variants were present in HapMap and were in high LD (r^2^ \> 0.5 in 1000 Genomes AFR population) with the lead variants in our previous HapMap imputed data, except for *TMEM18* rs62105306 (r^2^ = 0.17) which is absent in HapMap. In contrast, all three WHR~adjBMI~ lead variants were absent in HapMap and the lead variants at *ADAMTS9-AS2* and *TCF7L2-HABP2* were in low LD (r^2^ \< 0.5) with the lead variants in our previous HapMap imputed data \[[@pgen.1006719.ref011]--[@pgen.1006719.ref012]\]. We used conditional and joint association analyses to examine the genome-wide significant locus for secondary signals, but no additional independent signals were found.

![Locuszoom plots of six novel waist-to-hip ratio adjusted for BMI (WHR~adjBMI~) loci: (A) *TCF7L2/HABP2* and *SPRYD7/DLEU2* in men and women combined; and (B) *SSX2IP*, *PDE3B*, *CASC8*, and *ZDHHC1/HSD11B2* in women only. All plots use AFR LD from the 1000 Genomes phase 1 reference panel. In each plot, the most significant variant within a 1Mb regional locus is highlighted. *P*-values for all variants including the most significant variant are based on the African ancestry discovery phase only (AA-Discovery). In addition, for the most significant variant, *P*-values are annotated and illustrated from the African ancestry discovery and replication phases (AA-Discovery+Replication). SNP rs2472591 was available in the Europeans from the GIANT consortium effort and combined with the African ancestry discovery and replication phases (AA+EA).](pgen.1006719.g001){#pgen.1006719.g001}

10.1371/journal.pgen.1006719.t001

###### Novel and previously identified BMI and WHR~adjBMI~ loci at *P* \< 5×10^−8^ in African ancestry discovery and replication samples, and European ancestry replication samples.

![](pgen.1006719.t001){#pgen.1006719.t001g}

  Lead variant by locus   AA Discovery   AA Replication   AA Discovery + Replication   EA    AA + EA                                                                                                                                                                                                                             
  ----------------------- -------------- ---------------- ---------------------------- ----- ------------------------------------------------------------- ---------------- ----- ------- --------------- ---------- ------ -------- --------------- ---------- ------ -------- --------------- ---------- ----------- --------- -----------
  BMI                     rs543874       1                177,889,480                  Yes   rs543874                                                      *SEC16B*         G/A   0.248   0.055 (0.008)   5.75E-11   0      42,681   0.057 (0.017)   6.59E-04   28.9   10,143   0.055 (0.008)   1.76E-13   4.36E-35    322,008   6.35E-46
  BMI                     rs62105306     2                633,660                      Yes   rs13021737                                                    *TMEM18*         T/C   0.751   0.056 (0.01)    1.55E-08   0      41,492   0.04 (0.02)     4.40E-02   49.4   10,143   0.053 (0.009)   2.17E-09   6.10E-21    244,176   3.04E-28
  BMI                     rs10938397     4                45,182,527                   Yes   rs10938397                                                    *GNPDA2*         G/A   0.243   0.053 (0.008)   3.76E-10   3.6    42,752   0.011 (0.017)   5.40E-01   54     10,143   0.044 (0.008)   3.95E-09   1.87E-38    320,955   5.60E-46
  BMI                     rs7708584      5                153,543,466                  Yes   rs7715256; rs7708584 [^a^](#t001fn002){ref-type="table-fn"}   *GALNT10*        A/G   0.307   0.059 (0.008)   1.05E-13   4.6    42,750   0.034 (0.016)   3.93E-02   6.2    10,143   0.054 (0.007)   4.21E-14   3.80E-07    234,015   4.35E-15
  BMI                     rs17057164     6                97,410,536                   Yes   rs974417 [^a^](#t001fn002){ref-type="table-fn"}               *KLHL32*         T/C   0.659   0.043 (0.008)   1.75E-08   0      42,751   0.025 (0.015)   9.97E-02   35.2   10,143   0.04 (0.007)    6.08E-09   7.44E-01    233,997   5.43E-03
  BMI                     rs17817964     16               53,828,066                   Yes   rs1558902                                                     *FTO*            T/C   0.117   0.067 (0.011)   5.48E-09   0      42,750   0.08 (0.025)    1.19E-03   49.2   10,143   0.069 (0.01)    2.72E-11   2.40E-139   321,602   1.13E-146
  BMI                     rs6567160      18               57,829,135                   Yes   rs6567160                                                     *MC4R*           C/T   0.197   0.062 (0.009)   2.74E-11   35.3   42,750   0.044 (0.019)   1.99E-02   33.5   10,143   0.059 (0.008)   2.29E-12   8.23E-54    321,958   2.09E-64
  WHR~adjBMI~             rs66815886     3                64,703,394                   Yes   rs2371767                                                     *ADAMTS9-AS2*    G/T   0.457   0.07 (0.01)     3.90E-12   0      20,383   0.005 (0.033)   8.75E-01   42.1   2,711    0.064 (0.01)    2.46E-11   5.17E-19    145,257   9.13E-27
  WHR~adjBMI~             rs116718588    10               115,189,239                  No                                                                  *TCF7L2/HABP2*   A/G   0.955   0.114 (0.025)   5.88E-06   0      20,384   0.348 (0.084)   3.82E-05   45.6   2,711    0.134 (0.024)   3.22E-08   NA          NA        NA
  WHR~adjBMI~             rs2472591      13               50,536,360                   No                                                                  *SPRYD7/DLEU2*   T/A   0.206   0.05 (0.013)    9.72E-05   0      20,371   0.06 (0.049)    2.21E-01   0      2,160    0.05 (0.012)    4.36E-05   1.69E-05    140,431   3.53E-08

AA: African ancestry; BMI: body mass index; Chr: chromosome; EA: European ancestry; EAF: effect allele frequency; HetISq: heterogeneity measured by I-square; SE: standard error; WHR~adjBMI~: waist-to-hip ratio adjusted for BMI

^a^ lead published variants reported in African ancestry

### Sex-stratified analyses {#sec006}

In the sex-stratified meta-analysis in AA, four established BMI loci (*SEC16B*, *GALNT10*, *FTO* and *MC4R*) and one established WHR~adjBMI~ locus (*ADAMTS9-AS2*) were genome-wide significant among women ([S6 Table](#pgen.1006719.s017){ref-type="supplementary-material"}, [S8](#pgen.1006719.s008){ref-type="supplementary-material"} and [S9](#pgen.1006719.s009){ref-type="supplementary-material"} Figs). *ADAMTS9-AS2* showed a stronger association with WHR~adjBMI~ among women than among men (*P*~*het*~ = 0.02) ([S6 Table](#pgen.1006719.s017){ref-type="supplementary-material"}), consistent with findings among EA \[[@pgen.1006719.ref009]\]. On the other hand, although our observed *SEC16B* rs543874 effect size differences (0.064 vs. 0.038, *P*~*het*~ = 0.08) for BMI in women compared to men were similar to those previously observed among EA (0.060 vs. 0.034, *P*~*het*~ = 5.23×10^−5^) \[[@pgen.1006719.ref007]\], we did not observe statistically significant differences in effect size, likely due to a much smaller sample size and thus lower statistical power in our study. All these five loci were also genome-wide significant in the sex-combined meta-analyses. They were not further examined in subsequent sex-stratified analyses given their smaller sample sizes compared to the sex-combined analyses. In AA, additional novel loci were observed for association with BMI; these were variants in *IRX4/IRX2* among women, variants in *INTS10/LPL* and *MLC1* among men ([Fig 2](#pgen.1006719.g002){ref-type="fig"}), and for WHR~adjBMI~, variants in *SSX2IP* and *PDE3B* among women ([Fig 1B](#pgen.1006719.g001){ref-type="fig"}, [Table 2](#pgen.1006719.t002){ref-type="table"}). In meta-analyses including both AA and EA, two additional novel loci at *CASC8* and *ZDHHC1/HSD11B2* were identified for WHR~adjBMI~ in women ([Table 2](#pgen.1006719.t002){ref-type="table"}, [Fig 1B](#pgen.1006719.g001){ref-type="fig"}). Among all loci, the effect sizes of six variants (*IRX4/IRX2*, *INTS10/LPL*, *MLC1*, *ADAMTS9-AS2*, *PDE3B* and *CASC8*) were nominally significant different between men and women in AA (*P*~*het*~ \< 0.05) ([S6 Table](#pgen.1006719.s017){ref-type="supplementary-material"}).

![Locuszoom plots for three novel BMI loci: (A) *IRX4/IRX2* in women only; and (B) *INTS10/LPL* and *MLC1* in men only. All plots use AFR LD from the 1000 Genomes phase 1 reference panel. In each plot, the most significant variant within a 1Mb regional locus is highlighted. *P*-values for all variants including the most significant variant are based on the African ancestry discovery phase only (AA-Discovery). In addition, for the most significant variant, *P*-values are annotated and illustrated from the African ancestry discovery and replication phases (AA-Discovery+Replication).](pgen.1006719.g002){#pgen.1006719.g002}

10.1371/journal.pgen.1006719.t002

###### Additional novel BMI and WHR~adjBMI~ loci at *P* \< 5×10^−8^ in sex-stratified analyses of African ancestry discovery and replication samples.

![](pgen.1006719.t002){#pgen.1006719.t002g}

  Lead variant by locus   AA Discovery   AA Replication   AA Discovery + Replication   EA            AA + EA                                                                                                                                                                        
  ----------------------- -------------- ---------------- ---------------------------- ------------- ------------------- ----- ------- --------------- ---------- ------ -------- ---------------- ---------- ------ ------- --------------- ---------- -------- ---------- ------- ----------
  BMI                     Women          rs112778462      5                            2,177,693     *IRX4/ IRX2*        A/G   0.023   0.159 (0.035)   6.06E-06   35.4   25,792   0.219 (0.059)    2.11E-04   47.6   6,984   0.175 (0.03)    7.21E-09   32,776   NA         NA      NA
  BMI                     Men            rs149352150      8                            19,736,154    *INTS10/ LPL*       G/A   0.013   0.341 (0.058)   4.29E-09   0      15,179   -0.034 (0.163)   8.35E-01   1.0    2,147   0.299 (0.055)   4.68E-08   17,326   NA         NA      NA
  BMI                     Men            rs56330886       22                           50,493,427    *MLC1*              G/T   0.189   0.096 (0.016)   4.81E-09   3.3    15,721   0.063 (0.052)    2.21E-01   0.2    2,147   0.093 (0.016)   2.88E-09   17,868   NA         NA      NA
  WHR~adjBMI~             Women          rs140858719      1                            85,203,061    *SSX2IP*            G/A   0.994   0.506 (0.093)   5.07E-08   0      11314    0.403 (0.487)    4.08E-01   0      834     0.502 (0.091)   3.69E-08   12,148   NA         NA      NA
  WHR~adjBMI~             Women          rs378854         8                            128,323,819   *CASC8*             C/T   0.787   0.062 (0.015)   3.34E-05   4.5    15,600   0.034 (0.054)    5.29E-01   73.2   1,730   0.060 (0.014)   2.99E-05   17,330   3.70E-06   85325   3.26E-09
  WHR~adjBMI~             Women          rs185693786      11                           14,804,296    *PDE3B*             G/A   0.930   0.122 (0.023)   2.01E-07   0      15,601   0.17 (0.085)     4.50E-02   21.6   1,730   0.125 (0.023)   2.98E-08   17,331   NA         NA      NA
  WHR~adjBMI~             Women          rs6499129        16                           67,458,251    *ZDHHC1/ HSD11B2*   A/C   0.434   0.045 (0.012)   1.12E-04   30.9   15,588   0.071 (0.042)    9.29E-02   41.2   1,730   0.047 (0.011)   3.07E-5    17,318   4.13E-05   86328   4.84E-08

AA: African ancestry; BMI: body mass index; Chr: chromosome; EA: European ancestry; EAF:effect allele frequency; HetISq: heterogeneity measured by I-square; SE: standard error; WHR~adjBMI~: waist-to-hip ratio adjusted for BMI

### Replication in children {#sec007}

We evaluated the seven sex-combined and three sex-specific genome-wide significant BMI loci for associations in 7,222 AA children (3,552 boys and 3,670 girls). All lead variants displayed directional consistency, and five of these including *SEC16B*, *TMEM18*, *GNPDA2*, *GALNT10* and *MC4R* showed nominal associations with BMI (*P* \< 0.05, *P*~*binomial*~ = 4.70×10^−8^) ([S7 Table](#pgen.1006719.s018){ref-type="supplementary-material"}), supporting the role of these loci in modulating adiposity in AA children. WHR~adjBMI~ data were not available in the cohorts of children.

### Functional characterization of novel loci {#sec008}

We used multiple complementary approaches to elucidate the putative causal genes and/or variants associated with the nine novel BMI and WHR~adjBMI~ loci from the sex-combined and sex-stratified analyses, including annotating nearby coding variants, cis-expression quantitative trait loci (cis-eQTL) analyses, and functional regulatory genomic element analyses. One missense variant in *PLEKHG4*, rs8044843, was in high LD (r^2^ = 0.75 in AFR) with rs6499129 associated with WHR~adjBMI~ in women ([S8 Table](#pgen.1006719.s019){ref-type="supplementary-material"}). We did not identify any coding variants in high LD (r^2^\>0.7) with other lead variants within the flanking 1Mb-regions. Regulatory element analyses using RegulomeDB \[[@pgen.1006719.ref024]\] and HaploReg \[[@pgen.1006719.ref025]\] revealed that proxies (r^2^ = 0.73--0.84) to lead variants at three WHR~adjBMI~ loci (*SPRYD7/DLEU2*, *PDE3B*, and *ZDHHC1/HSD11B2)* were associated with transcription factor binding, DNase peak, promoter or enhancer histone marks ([S8 Table](#pgen.1006719.s019){ref-type="supplementary-material"}). In addition, the lead variant rs2472591 at *SPRYD7/DLEU2* was in high LD (r^2^ = 0.85) with rs790943, a cis-eQTL associated with expression of the nearby gene, *TRIM13*, in blood dendritic cells in tuberculosis patients \[[@pgen.1006719.ref026]\] ([S9 Table](#pgen.1006719.s020){ref-type="supplementary-material"}), suggesting the associations at the *SPRYD7/DLEU2* locus may be involved in the regulation of nearby gene expression at *TRIM13*.

### Cross-trait associations of novel loci {#sec009}

We searched the NHGRI-EBI GWAS \[[@pgen.1006719.ref027]\] and Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) \[[@pgen.1006719.ref028]\] catalogs to assess if any of the nine novel lead variants were in high LD with variants that were genome-wide significantly (*P* \< 5×10^−8^) or nominally (*P* \< 0.05) associated with related anthropometric and cardiometabolic traits or gene expression in prior studies. Although a few lead variants were physically close (\<500 kb) to GWAS loci for related traits in the NHGRI-EBI GWAS Catalog (Figs [1](#pgen.1006719.g001){ref-type="fig"} and [2](#pgen.1006719.g002){ref-type="fig"}), none of our lead variants were in high LD with the previously associated lead variants. Additionally, there were no nearby associations for novel BMI loci in the GRASP Catalog. Of the novel variants associated with WHR~adjBMI~, rs2472591 at *SPRYD7/DLEU2*, rs378854 near *MYC*, and rs6499129 near *ZDHHC1/HSD11B2* were in high LD (r^2^ \> 0.7) with previously-reported WHR~adjBMI~ variants, but they did not reach genome-wide significance (*P* \> 2×10^−5^) \[[@pgen.1006719.ref003]\] ([S9 Table](#pgen.1006719.s020){ref-type="supplementary-material"}). Other nearby associations with related cardiometabolic traits include chronic kidney disease (CKD), high density lipoprotein cholesterol (HDL-C), anthropometric traits (BMI, height, and birth weight), blood pressure (systolic blood pressure and hypertension), diabetes-related traits (blood glucose and HOMA-IR), and gene expression of several genes (e.g. *ATP6V0D1*, *ZDHHC1*, *DUS2L*, *AGRP*, *GFOD2* and *LRRC29*).

Evaluation of established European loci in African ancestry populations {#sec010}
-----------------------------------------------------------------------

### Conditional analysis in GWAS loci {#sec011}

Among the six BMI (*SEC16B*, *TMEM18*, *GNPDA2*, *GALNT10*, *FTO* and *MC4R*) and one WHR~adjBMI~ (*ADAMTS9-AS2*) genome-wide significant loci in AA that were previously reported in EA \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\], we tested whether the African derived lead variants were independent of the reported European signals by conditioning on the European lead variants or their surrogates. For three of the BMI loci (*SEC16B*, *GNPDA2* and *MC4R*), our lead variants are the same as those reported in the previous literature \[[@pgen.1006719.ref007]\]. For all other loci, the lead variants demonstrated substantially lower significance upon conditional analysis, suggesting that the African ancestry results represented the same association signals as previously reported in GWAS performed predominantly in EA populations ([S10 Table](#pgen.1006719.s021){ref-type="supplementary-material"}).

### SNP transferability {#sec012}

We further examined all sex-combined and sex-stratified BMI and WHR~adjBMI~ loci identified from previous EA studies \[[@pgen.1006719.ref007]--[@pgen.1006719.ref009]\] in our AA data. Among 176 EA lead variants from 170 BMI loci, 119 variants displayed directionally consistent associations with BMI in our data, 31 of these were nominally significant at *P* \< 0.05 (*P*~*binomial*~ = 2.2×10^−18^ among 176 variants). Among 84 EA lead variants from 65 WHR~adjBMI~ loci, 69 variants displayed directionally consistent associations with WHR~adjBMI~, and 23 of these were nominally significant (*P*~*binomial*~ = 5.3×10^−19^ among 84 variants) ([S11 Table](#pgen.1006719.s022){ref-type="supplementary-material"}). EA lead variants in 11 BMI and 3 WHR~adjBMI~ loci showed directional consistency and significant associations after correction for multiple comparisons (*P* \< 1.92×10^−4^). Among the 54 nominally transferable lead variants for BMI and WHR~adjBMI~, 45% and 43% of the effect sizes, respectively, were larger in the EA than the AA populations. In addition, 65% of the frequencies of the trait-raising alleles were higher in the EA populations for both traits. The correlations of both effect sizes and allele frequency of the transferable variants were high (0.74 and 0.79, respectively) for BMI but weak (0.19 and 0.37, respectively) for WHR~adjBMI~ ([S11 Fig](#pgen.1006719.s011){ref-type="supplementary-material"}). The significant but low proportion of lead variants that were transferable from EA to AA (18% for BMI and 27% for WHR~adjBMI~) suggests either that many loci are not implicated in AA or population differences in LD mask the detection of associated variants in AA. On the other hand, those variants that were transferable explain similar levels of variances for BMI in both populations, but not for WHR~adjBMI~.

### Locus transferability {#sec013}

We further investigated locus transferability in EA loci derived from sex-combined and sex-stratified analyses by considering varying LD between EA and AA populations. [S12 Table](#pgen.1006719.s023){ref-type="supplementary-material"} reports the most significant lead regional variants in our AA sex-combined and sex-stratified data within 0.1cM region of the previously published EA loci (from 176 BMI and 84 WHR~adjBMI~ lead variants) \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\]. Forty-five (26%) lead regional variants from BMI loci remained significant (*P*~*locus*~ \< 0.05) after adjustment for the number of independent variants tested at each locus. Sixteen (36%) and 22 (49%) of these 45 lead regional variants are in LD (r^2^\>0.2) with the EA BMI lead variants using 1000 Genomes AFR and CEU LD, respectively. Twenty-five of these variants are highly correlated with EA lead variants(r^2^\>0.7 in CEU) or had ≥1 standard error decrease in effect sizes after conditional analyses, representing same association signals as in EA populations. Twenty-one (32%) lead regional variants for WHR~adjBMI~ loci remained significant. Nine (43%) and seven (33%) of the 21 lead regional variants was in LD with the EA lead variant using 1000 Genomes AFR and CEU LD, respectively. Seven of these variants represented the same EA association in conditional analyses ([S12 Table](#pgen.1006719.s023){ref-type="supplementary-material"}).

Fine mapping of novel AA loci and EA-AA transferable established loci {#sec014}
---------------------------------------------------------------------

Among the locus-wide significant established loci (44 for BMI given two of 45 lead regional variants were identical in two loci, and 21 for WHR~adjBMI~), and novel loci (three for BMI and six for WHR~adjBMI~) derived from the sex-combined and sex-stratified analyses, we performed fine mapping to localize putative causal variants. We constructed 99% credible sets containing variants that jointly account for 99% posterior probability of driving the association in a locus using the corresponding sex-combined or sex-stratified meta-analysis results from AA, EA and combined ancestry ([S13 Table](#pgen.1006719.s024){ref-type="supplementary-material"}). A smaller number of variants in a credible set represent a higher resolution of fine mapping and we considered a credible set containing ≤ 20 variants as "tractable' for follow up. The credible sets in the EA analyses were generally smaller than those in the AA given their larger sample size. As compared to the EA analyses, the number of tractable loci in the meta-analyses of AA and EA increased from 23 to 26 for BMI, and from 14 to 17 for WHR~adjBMI~.

Among these 43 tractable loci, the lead variants in the combined ancestry analyses had posterior probability ≥ 0.95 in six BMI loci (*SEC16B*, *TLR4*, *STXBP6*, *NLRC3*, *FTO* and *MC4R*) and seven WHR~adjBMI~ loci (*DCST2*, *PPARG*, *ADAMTS9*, *SNX10*, *KLF13*, *CMIP* and *PEMT*) ([S13 Table](#pgen.1006719.s024){ref-type="supplementary-material"}). Functional characterization of variants within the tractable credible sets revealed two loci contain nonsynonymous variants (*ADCY3*: rs11676272 S107P; *SH2B1*: rs7498665 T484A from the *ATP2A1* locus), but they had low posterior probability to drive the respective associations (0.02 and 0.15, respectively) ([S14 Table](#pgen.1006719.s025){ref-type="supplementary-material"}). On the other hand, the *ADCY3* non-coding variants rs10182181 and rs6752378 had higher posterior probability (0.26--0.72) and are cis-eQTLs of *ADCY3* and nearby genes. Several BMI loci including *MTCH2*, *MAP2K5*, *NLRC3* and *ATP2A1*, and WHR~adjBMI~ loci including *TBX15-WARS2* and *FAM13A*, also contained cis-eQTL variants regulating nearby gene expression in subcutaneous and/or visceral adipose tissue ([S14 Table](#pgen.1006719.s025){ref-type="supplementary-material"}).

Discussion {#sec015}
==========

In our large-scale meta-analyses of GWAS in up to 52,895 and 23,095 individuals of African ancestry for BMI and WHR~adjBMI~, respectively, we identified three novel (*IRX4/IRX2*, *INTS10/LPL* and *MLC1*) and seven established (*SEC16B*, *TMEM18*, *GNPDA2*, *GALNT10*, *KLHL32*, *FTO* and *MC4R*) BMI loci, as well as three novel (*TCF7L2/HABP2*, *SSX2IP* and *PDE3B*) and one established (*ADAMTS9-AS2*) WHR~adjBMI~ loci in either sex-combined or sex-stratified analyses. By employing a recently developed method \[[@pgen.1006719.ref023]\] to impute European GWAS summary statistics to the denser 1000 Genomes reference panel, followed by meta-analyses of both African and European ancestry individuals, we also identified three additional novel loci (*SPRYD7/DLEU2*, *CASC8* and *ZDHHC1/ HSD11B2*) for WHR~adjBMI~. While all lead variants from established loci are common (MAF ≥ 5%), four of the nine lead variants from novel loci were low frequency (0.5% ≤ MAF \< 5%). In addition, the lead variants from established loci including *TMEM18* and *ADAMTS9-AS2* were absent in HapMap. Overall, these results suggest the deeper genome coverage and/or improved imputation quality using 1000 Genomes, and complemented with additional sex-stratified analyses, facilitate the discovery of novel loci and identification of variants with stronger effects in established loci.

Among the novel sex-specific BMI loci (*IRX4/IRX2*, *INTS10/LPL* and *MLC1*), we did not identify any putative coding variants or regulatory regions underlying our association signals. Additionally, no associations have been reported with other metabolic traits in these novel BMI-associated signals. The first lead variant rs112778462 is located between the *IRX4* and *IRX2* genes which are members of the Iroquois homeobox gene family. *IRX2* expression has been associated with deposition of fat in the subcutaneous abdominal adipose tissue but no sex difference was observed \[[@pgen.1006719.ref029]--[@pgen.1006719.ref030]\]. *Irx4* knock out mice demonstrated cardiomyopathy with compensated increased *Irx2* expression \[[@pgen.1006719.ref031]\]. The second lead variant rs149352150 is located between the *INTS10* and *LPL* genes. *LPL* encoded lipoprotein lipase is expressed in several tissues including adipose to mediate triglyceride hydrolysis and lipoprotein uptake. The serum LPL mass \[[@pgen.1006719.ref032]\] and LPL activity and fat cell size of adipose tissues at gluteus and thigh \[[@pgen.1006719.ref033]\] have been reported to be higher in women than in men. Previous GWAS demonstrated association of *LPL* with triglycerides and HDL cholesterol \[[@pgen.1006719.ref034]--[@pgen.1006719.ref035]\]. However, the reported lead variant rs12678919 was not in strong LD with rs149352150 (r^2^ = 0.005 in AFR and 0.006 in EUR). The third lead variant rs56330886 is located in a gene-rich region on chromosome 22q13 including *MLC1*. No biological candidates are identified in this region, therefore further analyses may be needed to explain the causative mechanism for this association signal.

Among the novel WHR~adjBMI~ loci, rs116718588 is located between *TCF7L2* and *HABP2*. *TCF7L2* is the most significant type 2 diabetes locus in African Americans \[[@pgen.1006719.ref036]\] and other populations \[[@pgen.1006719.ref037]\]. However, rs116718588 was not in LD (r^2^ \< 0.01 in AFR) with the reported type 2 diabetes associated variants. The second lead variant rs2472591 is located near *SPRYD7*, *DLEU2* and *TRIM13*. This locus was associated with height in previous GWAS \[[@pgen.1006719.ref006]\], but rs2472591 was not associated with height in our study (*P* \> 0.05), suggesting different variants in this locus regulate different measures of body size. In addition, a surrogate of rs2472591, rs790943, is a cis-eQTL for *TRIM13* \[[@pgen.1006719.ref026]\] suggesting it may be the target gene. *TRIM13* encodes an E3 ubiquitin-protein ligase involved in endoplasmic reticulum-associated degradation. The third lead variant rs140858719 is located between *SSX2IP* and *LPAR3*. *LPAR3* is a plausible candidate as it encodes a receptor for lysophosphatidic acid (LPA). The autotaxin/LPA pathway mediates diverse biological actions including activation of preadipocyte proliferation \[[@pgen.1006719.ref038]\], suppression of brown adipose differentiation \[[@pgen.1006719.ref039]\], and promotion of systematic inflammation \[[@pgen.1006719.ref040]\] which lead to increased risk for cardiometabolic diseases including obesity and insulin resistance \[[@pgen.1006719.ref041]--[@pgen.1006719.ref042]\]. LPA receptor 1 which is highly expressed in adipocytes and the gut primarily mediates these effects \[[@pgen.1006719.ref043]\]. It has also been reported that LPA, via LPA1 and LPA3 receptors, mediated leukocytes recruitment and pro-inflammatory chemokine secretion during inflammation \[[@pgen.1006719.ref044]\]. The fourth lead variant rs185693786 is located at intron 2 of *PDE3B*. The association signal spanned a large genomic region and harbors GWAS loci for adiponectin and height. Phosphodiesterase 3B is critical for mediating insulin/IGF-1 inhibition of cAMP signaling in adipocytes, liver, hypothalamus and pancreatic β cells \[[@pgen.1006719.ref045]\]. *Pde3b*-knockout mice exhibited multiple alterations in regulation of lipolysis, lipogenesis, and insulin secretion, as well as signs of peripheral insulin resistance \[[@pgen.1006719.ref046]\]. PDE3B expression has been reported to be higher in microvascular endothelial cell culture derived from skeletal muscles from male rats than in female rats \[[@pgen.1006719.ref047]\]. The fifth lead variant rs6499129 is located intergenic between *ZDHHC1* and *HSD11B2*. *HSD11B2* encodes 11β-hydroxysteroid dehydrogenase type 2 which converts the active glucocorticoids to inactive metabolites. HSD2 activity was elevated in severe obesity and negatively associated with insulin sensitivity \[[@pgen.1006719.ref048]\]. HSD2 expression is higher in omental than abdominal subcutaneous adipose tissue which may contribute to adipocyte hypertrophy and visceral obesity \[[@pgen.1006719.ref049]\]. The sixth lead variant rs378854 is located at the long non-coding RNA *CASC8*. Associations of variants at *CASC8* have been reported for various cancers \[[@pgen.1006719.ref050]--[@pgen.1006719.ref052]\] but no association was reported for cardiometabolic traits.

In our SNP and locus transferability analyses, a moderate number of EA-derived BMI and WHR~adjBMI~ associated variants shared the same trait-raising alleles and displayed nominally significant associations in AA individuals, similar to previous findings \[[@pgen.1006719.ref011]--[@pgen.1006719.ref012]\]. While the BMI variants were similar in terms of their effect sizes and frequencies of trait-raising alleles between EA and AA populations, there were more discrepancies for WHR~adjBMI~ variants. In addition, a substantial proportion of lead regional variants in AA were not in strong LD with EA lead variants, suggesting AA populations either have different association signals or the results may be spurious. Taken together, only \<30% of EA loci were associated with BMI and WHR~adjBMI~ in AA.

Trans-ethnic fine mapping improved resolution to refine putative causal variant(s) in some loci as compared to using EA studies alone. In the meta-analyses of AA and EA GWAS, four BMI loci (*SEC16B*, *STXBP6*, *FTO* and *MC4R*) and six WHR~adjBMI~ loci (*PPARG*, *ADAMTS9*, *SNX10*, *KLF13*, *CMIP* and *PEMT*) only contained one variant in the 99% credible sets. Among 16 BMI and 3 WHR~adjBMI~ loci that were examined in both the previous trans-ethnic meta-analysis studies using HapMap imputation \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\] and the present study, the number of variants and the interval of credible sets were either the same or lower in the present study for 13 and 15 loci, respectively. The majority of credible variants are non-coding in those sets containing ≤ 20 variants. Several of them located at the *MTCH2*, *MAP2K5*, *NLRC3*, *ATP2A1*, *TBX15-WARS2* and *FAM13A* loci are cis-eQTL variants regulating nearby gene expression in subcutaneous and/or visceral adipose tissue, suggesting the putative causal variants may have a regulatory role instead of directly altering protein structure and function. Despite the low posterior probabilities, the coding changes of credible variants at *ADCY3* and *SH2B1* suggest that they may be the causal genes in the respective loci modulating BMI. Further studies are warranted to delineate putative causal variants including functional annotation in trans-ethnic fine mapping efforts \[[@pgen.1006719.ref053]\].

Our large-scale GWAS meta-analyses in African ancestry individuals imputed to the 1000 Genomes reference panel, complemented by imputation of European GWAS using summary statistics and additional sex-stratified analyses, boosts the study power and improves resolution, leading to the identification of nine novel loci and fine mapping 37 loci with tractable credible sets. We observed significant associations for variants with MAF ≥ 0.5%, but rare variants were unlikely to be detected due to limited power and poor imputation quality. Large scale sequencing studies are needed to evaluate the contribution of rare variants in modulating complex traits such as BMI and WHR. Given the substantially larger sample size in European than in African ancestry samples, the trans-ethnic fine mapping results are largely driven by variants showing strong associations in Europeans. Future trans-ethnic studies including additional non-European populations will further improve the fine mapping effort.

Materials and methods {#sec016}
=====================

Study design {#sec017}
------------

We used a three-stage design to evaluate genetic associations with BMI and WHR~adjBMI~ in sex-combined and sex-stratified samples ([S1 Fig](#pgen.1006719.s001){ref-type="supplementary-material"}). Stage 1 included GWAS meta-analyses in AA individuals and stage 2 included replication of top associations from stage 1. Stage 3 included meta-analysis of top associations from stages 1 and 2 AA studies and EA meta-analysis results. In the discovery stage 1 of AAAGC, 17 GWAS of up to 42,752 AA individuals (16,559 men and 26,193 women; 41,696 African Americans and 1,056 Africans) were included for the BMI analyses. A total of 10 GWAS of up to 20,384 AA individuals (4,783 men and 15,601 women; all African Americans) were included for the WHR~adjBMI~ analyses. For variants with *P* \< 1×10^−4^ in either the sex-combined or the sex-stratified meta-analyses, stage 2 replication was performed in additional AA individuals from AAAGC (N = 10,143 for BMI, N = 2,711 for WHR~adjBMI~), followed by meta-analysis with EA individuals from the GIANT consortium (322,154 for BMI, 210,086 for WHR~adjBMI~). Variants that reached genome-wide significance (*P* \< 5×10^−8^) were assessed for associations with BMI in two cohorts of children (N = 7,222). All AA participants in these studies provided written informed consent for the research, and approval for the study was obtained from the ethics review boards at all participating institutions. Detailed descriptions of each participating study and measurement and collection of height, weight, waist and hip circumferences are provided in [S1 Text](#pgen.1006719.s026){ref-type="supplementary-material"}, [S1](#pgen.1006719.s012){ref-type="supplementary-material"} and [S2](#pgen.1006719.s013){ref-type="supplementary-material"} Tables.

Genotyping, imputation and quality control {#sec018}
------------------------------------------

Genotyping in each study was performed with Illumina or Affymetrix genome-wide SNP arrays. Pre-phasing and imputation of missing genotypes in each study was performed using MaCH/ minimac \[[@pgen.1006719.ref020]\] or SHAPEIT2/IMPUTEv2 \[[@pgen.1006719.ref021]--[@pgen.1006719.ref022]\] using the 1000 Genomes Project cosmopolitan reference panel (Phase I Integrated Release Version 3, March 2012) \[[@pgen.1006719.ref018]\]. The details of the array, genotyping and imputation quality-control procedures and sample exclusions for each study are listed in [S3 Table](#pgen.1006719.s014){ref-type="supplementary-material"}. In general, samples reflecting duplicates, low call rates, gender mismatch, or population outliers were excluded. Variants were excluded by the following criteria: call rate \< 0.95, minor allele count (MAC) ≤ 6, Hardy-Weinberg Equilibrium (HWE) *P* \< 1×10^−4^, imputation quality score \< 0.3 for minimac or \< 0.4 for IMPUTE, or absolute allele frequency difference \> 0.3 compared with expected allele frequency (calculated as 1000 Genomes frequency of AFR × 0.8 + EUR × 0.2).

Performance of 1000 Genomes imputation in African ancestry {#sec019}
----------------------------------------------------------

We evaluated the performance of 1000 Genomes imputation using the largest study, the Women's Health Initiative (WHI) (N = 8,054). A total of 25.1 million variants with MAF ≥ 0.1% were imputed to the 1000 Genomes reference panel. Of these, 98.1% (8.8 million) common variants, 95.4% (9.3 million) low frequency variants (0.5% ≤ MAF \< 5%), and 72.5% (4.6 million) rare variants (0.1% ≤ MAF \< 0.5%) were well imputed with IMPUTE info scores ≥ 0.3 ([S4 Table](#pgen.1006719.s015){ref-type="supplementary-material"}). Notably, these frequencies are slightly lower than those obtained by imputation using 1000 Genomes phase 1 interim reference panel in Europeans \[[@pgen.1006719.ref054]\]. However, 72.6%, 95.5% and 99.5% of the common, low frequency and rare variants, respectively, from the 1000 Genomes reference panel were not present in the HapMap and therefore demonstrate deeper coverage of the genome, particularly for the low frequency and rare variants.

Study-level association analyses {#sec020}
--------------------------------

At all stages, genome-wide association analyses were performed by each of the participating studies. BMI was regressed on age, age squared, principal components and study site (if needed) to obtain residuals, separately by sex and case-control status, if needed. WHR was regressed on age, age squared, principal components, BMI and study site to obtain residuals, separately by sex and case-control status. Principal components were included to adjust for admixture proportion and population structure within each study. Residuals were inverse-normally transformed to obtain a standard normal distribution with mean of zero and standard deviation of one. For studies with unrelated subjects, each variant was tested assuming an additive genetic model with each trait by regressing the transformed residuals on the number of copies of the variant effect allele. The analyses were stratified by sex and case-control status (if needed). For studies that included related individuals, family based association tests were conducted that took into consideration the genetic relationships among the individuals. Sex stratified, case-control stratified and combined analyses were performed. Association results with extreme values (absolute beta coefficient or standard error ≥ 10), primarily due to small sample sizes and/or low minor allele count, were excluded for meta-analysis.

Imputation of European GWAS summary statistics to 1000 Genomes {#sec021}
--------------------------------------------------------------

The latest summary statistics of sex-combined and sex-stratified meta-analyses of BMI and WHR~adjBMI~ imputed to the HapMap reference panel in EA from the Genetic Investigation of ANthropometric Traits (GIANT) consortium were obtained from <http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files> \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\]. These association summary statistics were used to impute z-scores of unobserved variants at the 1000 Genomes Project EUR reference panel (Phase I Integrated Release Version 3) using the ImpG program \[[@pgen.1006719.ref023]\]. In brief, palindromic variants (AT/CG) and variants with allele mismatch with the reference were removed from the data. Using the ImpG-Summary method, the z-score of an unobserved variant was calculated as a linear combination of observed z-scores weighted by the variance-covariance matrix between variants induced by LD within a 1 Mb window from the reference haplotypes. The sample size of each unobserved variant was also interpolated from the sample sizes of observed variants using the same weighting method for z-score as $N_{i} = \sum_{t = 1}^{t = T}\frac{\left| w_{i,t} \right|}{\sum\left| w_{i,t} \right|}N_{t}$. Here, t = 1,2,....,T, where T is the number of observed variants, *w*~*i*,*t*~ is the element of the covariance matrix Σ~*i*,*t*~ for the unobserved variant *i* and the observed variant *t* within window. The performance of imputation was assessed by *r*^*2*^*pred*, with similar characteristics as the standard imputation accuracy metric *r*^*2*^*hat* \[[@pgen.1006719.ref020]\]. Results of variants with *r*^*2*^*pred* ≥ 0.6 were used in subsequent analyses.

Meta-analysis {#sec022}
-------------

In the discovery stage 1, association results were combined across studies in sex-combined and sex-stratified samples using inverse-variance weighted fixed-effect meta-analysis implemented in the program METAL \[[@pgen.1006719.ref055]\]. The study-specific λ values of association ranged from 0.97 to 1.05 for BMI, and 0.98 to 1.05 for WHR~adjBMI~ ([S3 Table](#pgen.1006719.s014){ref-type="supplementary-material"}). Genomic control correction \[[@pgen.1006719.ref056]\] was applied to each study before meta-analysis, and to the overall results after meta-analysis (λ = 1.07 for BMI, 1.01 for WHR~adjBMI~). Variants with results generated from \< 50% of the total sample size for each trait were excluded. After filtering, the numbers of variants reported in the meta-analyses were 17,972,087 for BMI, and 20,502,658 for WHR~adjBMI~.

Variants with *P* \< 1×10^−4^ in stage 1 sex-combined or sex-stratified meta-analyses were carried forward for replication in additional AA individuals (stage 2) and EA individuals (stage 3). For each of the replication AA studies, trait transformation and association were performed as in stage 1 and results were meta-analyzed using the inverse-variance method in METAL. For the replication study in EA, HapMap imputed summary statistics of each trait from the GIANT consortium were used to impute z-scores of unobserved variants at the 1000 Genomes.

In stages 1 and 2, meta-analysis results of AA studies were combined using the inverse-variance weighted method. In all stages including both AA and EA studies, meta-analysis results expressed as signed z-scores were combined using the fixed effect sample size weighted method in METAL due to the lack of beta and standard error estimates from the ImpG program \[[@pgen.1006719.ref023]\]. Evidence of heterogeneity of allelic effects between males and females, within and across stages were assessed by the *I*^*2*^ statistic in METAL. Genome-wide significance was declared at *P* \< 5×10^−8^ from each of the sex-combined and sex-stratified meta-analysis including AA and/or combined AA and EA individuals. Difference in effects between men and women was assessed using Cochran's Q test and nominal *P*~*het*~ \< 0.05 declared as significant. A lead variant in a locus was defined as the most significant variant within a 1 Mb region. A novel locus was defined as a lead variant with distance \> 500 kb from any established lead variants reported in previous studies. By convention, a locus was named by the closest gene(s) to the lead variant.

Conditional and joint analyses of summary statistics {#sec023}
----------------------------------------------------

For the genome-wide significant loci identified in sex-combined and sex-stratified analyses in AA (stages 1+2), we used the program GCTA \[[@pgen.1006719.ref057]--[@pgen.1006719.ref058]\] to select the top independent associated variants from summary statistics of the meta-analyses. This method uses the LD correlations between variants estimated from a reference sample to perform an approximate conditional association analysis. We used 8,054 unrelated individuals of African ancestry from the WHI cohort with \~15.7M variants available as the reference sample for LD estimation. To select the top independent variants in the discovery and replication meta-analysis results, we first selected all variants that had *P* \< 5×10^−8^ and conducted analysis conditioning on the selected variants to search for the top variants iteratively via a stepwise model to select the independent variants from this list. Then we proceeded to condition the rest of the variants that had *P* \> 5×10^−8^ on the list of independent variants in the same fashion until no variant had conditional *P* that passed the significance level *P* \< 5×10^−8^. Finally, all the selected variants were fitted jointly in the model for effect size estimation.

We also tested if the genome-wide significant variants identified from sex-combined GWAS in AA and the locus-wide significant variants identified from sex-combined and sex-specific locus transferability studies in AA were independent from nearby established loci identified from EA studies \[[@pgen.1006719.ref007]--[@pgen.1006719.ref008]\]. First, the published lead variants from EA studies were used to search for all surrogate variants that were in high LD (r^2^\>0.8 in 1000 Genomes Project EUR population). Second, these variants were pruned to select only variants in low LD in AA (r^2^\<0.3 in the 1000 Genomes Project AFR population) to avoid collinearity in conditional analysis. Third, association analysis was conducted on the AA significant variants conditioned on the selected EA lead and surrogate variants, using the program GCTA and estimated LD correlation from the WHI cohort. For genome-wide significant loci, an AA derived association signal is considered as independent from the established EA signals when the difference in--log*P* \<3 and difference in effect size \< 1 standard error after conditional analysis. For locus-wide significant loci, given the lower level of significance, independence is only considered as difference in effect size \< 1 standard error after conditional analysis.

SNP and locus transferability analyses {#sec024}
--------------------------------------

We investigated the transferability of EA BMI and WHR associated variants and loci in AA individuals from stage 1 sex-combined and sex-stratified meta-analyses. First, we tested for replication of lead variants previously reported to be associated with BMI (176 variants from 170 loci) and WHR~adjBMI~ (84 variants from 65 loci) at genome-wide significance in sex-combined and sex-stratified analyses from the GIANT consortium studies \[[@pgen.1006719.ref007]--[@pgen.1006719.ref009]\]. We defined SNP transferability as an EA lead variant sharing the same trait-raising allele at nominal *P* \< 0.05 in AA individuals. To account for differences in local LD structure across populations, we also interrogated the flanking 0.1cM regions of the lead variants to search for the best variants with the smallest association *P* in AA individuals. Locus-wide significance was declared as *P*~*locus*~ \< 0.05 by Bonferroni correction for the effective number of tests within a locus, estimated using the Li and Ji approach \[[@pgen.1006719.ref059]\].

Fine mapping analyses {#sec025}
---------------------

We compared the credible set intervals of established loci that showed locus-wide significance (*P*~*locus*~ \< 0.05) in the sex-combined or sex-specific analyses from this study in summary statistics datasets including the 1000 Genomes imputed results from GIANT, AAAGC and meta-analysis of GIANT and AAAGC. In each dataset, a candidate region is defined as the flanking 0.1cM region of the lead variant reported by the GIANT consortium. Under the assumption of one causal variant in a region of *M* variants, the posterior probability of a variant *j* with association statistics Z driving the association, *P*(*C*~*j*~\|*Z*), was calculated using the formula $P\left( C_{j} \middle| Z \right) = \frac{{\exp(\frac{1}{2}}{z_{j}^{2})}}{\sum_{j = 1}^{M}{exp\left( {\frac{1}{2}z_{j}^{2}} \right)}}$. A 99% credible set was constructed by ranking all variants by their posterior probability, followed by adding variants until the credible set has a cumulative posterior probability \> 0.99 \[[@pgen.1006719.ref053]\].

Bioinformatics {#sec026}
--------------

### Functional annotation of novel variants {#sec027}

To determine whether any of our nine novel GWAS lead variants identified in the sex-combined and sex-specific analyses might be tagging potentially functional variants, we identified all variants within 1 Mb and in LD (r^2^ \> 0.7, 1000 Genomes AFR) with our lead variants. As such, we identified 137 variants and annotated each of them using ANNOVAR \[[@pgen.1006719.ref060]\]. The predicted functional impact for coding variants were assessed via the Exome Variant Server (<http://evs.gs.washington.edu/EVS/>) for PhastCon, GERP \[[@pgen.1006719.ref061]\], and PolyPhen \[[@pgen.1006719.ref062]\], as well as SIFT \[[@pgen.1006719.ref063]\].

We further characterized the variants that were in LD with the novel variants using the web-based tool RegulomeDB (<http://regulomedb.org/>) \[[@pgen.1006719.ref024]\]. The variants that were likely to affect binding and linked to expression of a gene target (scores 1a-1f) based on "eQTL, transcription factor (TF) binding, matched TF motif, matched DNase footprint and DNase peak" or were only likely to affect binding (scores 2a-2c) based on "TF binding, matched TF motif, matched DNase footprint and DNase peak" were selected. For these variants, the sequence conservation (GERP and SiPhy \[[@pgen.1006719.ref064]\]), the epigenomic data from the Roadmap Epigenomic project (ChromHMM states corresponding to enhancer or promoter elements, histone modification ChIP-seq peaks, and DNase hypersensitivity data peaks), the regulatory protein binding from the ENCODE project, the regulatory motifs based on commercial, literature and motif-finding analysis of the ENCODE project, and the eQTLs from Genotype-Tissue Expression (GTEx) project \[[@pgen.1006719.ref065]\] were extract from web-based HaploReg v4 \[[@pgen.1006719.ref025]\]. For variants within the tractable credible sets in the fine mapping analyses, similar analyses were also conducted.

### Cross-trait associations {#sec028}

To assess whether the novel loci identified in the sex-combined and sex-specific analyses were associated with any related cardiometabolic and anthropometric traits, or may be in high LD with known eQTLs, we examined the NHGRI-EBI GWAS Catalog \[[@pgen.1006719.ref027]\] and the GRASP (Genome-Wide Repository of Associations Between SNPs and Phenotypes) catalog \[[@pgen.1006719.ref028]\] for reported variant-trait associations near our lead variants. We supplemented the catalogs with additional genome-wide significant associations of interest from the literature \[[@pgen.1006719.ref007]--[@pgen.1006719.ref009],[@pgen.1006719.ref066]\]. We used PLINK to identify variants within 1 Mb of lead variants. All variants within the specified regions with r^2^ \> 0.7 (1000 Genomes AFR) were retained from the catalogs for further evaluation.

Power analysis {#sec029}
--------------

Given our sample sizes in the discovery and replication stages in our African ancestry populations, we have \>80% power to detect variants explaining 0.08% variance for BMI that corresponds to effect sizes of 0.09 and 0.20 SD units for MAF of 0.05 and 0.01, respectively. For WHR~adjBMI~, we have \>80% power to detect variants explaining 0.18% variance that corresponds to effect sizes of 0.14 and 0.30 SD units for MAF of 0.05 and 0.01, respectively.
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